Castle Biosciences, Inc. - Common stock (CSTL)
CSTL moved a median of +0.06% 30 minutes after news, and -0.24% by the close. How CSTL actually reacts to news — the realized, point-in-time move the market made, measured across 524 labeled events over the last three years with zero look-ahead.
CSTL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 522 |
| 30-min | +0.06% | 53% | 524 |
| 60-min | +0.04% | 50% | 524 |
| to close | -0.24% | 45% | 523 |
| Middle 50% of CSTL reactions | -1.00% to +1.13% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 524 |
Half of all Castle Biosciences, Inc. - Common stock news events land between -1.00% and +1.13% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CSTL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 41 | -0.31% | 39% | -0.23% |
| Price-target raises | 16 | -0.51% | 44% | -0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CSTL ranks against every other measured name →
That’s how CSTL usually reacts — get an email when it moves on news →Email me when CSTL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CSTL's baseline. Nothing else.
Recent CSTL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 | Press release | PR Newswire | -0.84% | +2.02% | |
| ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus | Press release | PR Newswire | +0.21% | +0.27% | |
| Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management | Press release | PR Newswire | +0.39% | -2.34% | |
| New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus | Press release | PR Newswire | -0.73% | +0.34% | |
| New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ | Press release | PR Newswire | -1.85% | +1.76% | |
| Castle Biosciences to Open New Laboratory Facility in Scottsdale | Press release | PR Newswire | -2.07% | -1.91% | |
| New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus | Press release | PR Newswire | +0.16% | +5.53% | |
| JAAD Publication Shows Improved Performance of DecisionDx®-SCC | Press release | PR Newswire | -0.17% | +1.09% | |
| SciBase receives additional order from Castle Biosciences, advancing the collaboration | Press release | PR Newswire | +0.57% | +0.80% | |
| Castle Biosciences to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +1.57% | +1.60% | |
| Castle Biosciences Approved for Dual Listing on Nasdaq Texas | Press release | PR Newswire | +0.14% | +1.52% | |
| Form CERT CASTLE BIOSCIENCES INC | SEC filing · Form CERT | SEC EDGAR | +0.14% | +1.52% | |
| Form 8-A12B CASTLE BIOSCIENCES INC | SEC filing · Form 8-A12B | SEC EDGAR | -1.29% | -4.24% | |
| Castle Biosciences Reports Second Quarter 2026 Results | Press release | PR Newswire | +5.04% | -2.78% | |
| Form 10-Q CASTLE BIOSCIENCES INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.04% | -2.78% | |
| Form 8-K CASTLE BIOSCIENCES INC For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +5.04% | -2.78% | |
| Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference | Press release | PR Newswire | -0.51% | +1.97% | |
| The Melanoma Research Foundation Launches its Annual Cleveland 5K Fundraiser with a Goal of $155,000 in Support of Melanoma Research, Education and Advocacy | Press release | PR Web | — | +1.55% | |
| Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test | Press release | PR Newswire | +0.89% | +4.12% | |
| Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 | Press release | PR Newswire | +1.73% | +3.63% | |
| DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy | Press release | PR Newswire | +1.43% | +7.19% | |
| Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal | Press release | PR Newswire | +1.71% | +1.47% | |
| Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.05% | -0.42% | |
| Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus | Press release | PR Newswire | -0.73% | -1.02% | |
| Form 8-K CASTLE BIOSCIENCES INC For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -0.52% | |
| Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference | Press release | PR Newswire | +1.68% | -1.95% | |
| Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation | Press release | PR Newswire | +0.11% | -1.69% | |
| Castle Biosciences Reports First Quarter 2026 Results | Press release | PR Newswire | +1.55% | -13.45% | |
| Form 10-Q CASTLE BIOSCIENCES INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.55% | -13.45% | |
| Form 8-K CASTLE BIOSCIENCES INC For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +1.55% | -13.45% | |
| Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month | Press release | PR Newswire | +0.00% | -3.26% | |
| New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus | Press release | PR Newswire | +2.71% | +3.19% | |
| Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS | Press release | PR Newswire | +0.26% | -2.42% | |
| The Melanoma Research Foundation Launches its Inaugural Washington DC 5K Fundraiser with a Goal of $115,000 in Support of Melanoma Research, Education and Advocacy | Press release | PR Web | -0.32% | -0.59% | |
| Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 | Press release | PR Newswire | +0.90% | +1.03% | |
| Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year | Press release | PR Newswire | +0.00% | -0.73% | |
| Form ARS CASTLE BIOSCIENCES INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.82% | -1.87% | |
| Form DEF 14A CASTLE BIOSCIENCES INC For: May 28 | SEC filing · Form DEF | SEC EDGAR | +0.14% | -1.47% | |
| Form DEFA14A CASTLE BIOSCIENCES INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.14% | -1.47% | |
| Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 | Press release | PR Newswire | +0.16% | -4.35% | |
| Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB | Press release | GlobeNewswire | -0.12% | +0.45% | |
| DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk | Press release | GlobeNewswire | -0.09% | +0.78% | |
| Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB | Press release | GlobeNewswire | +0.43% | +0.87% | |
| Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas | Press release | GlobeNewswire | +0.81% | +1.55% | |
| Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results | Press release | GlobeNewswire | -4.24% | -1.00% | |
| Form 10-K CASTLE BIOSCIENCES INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.24% | -1.00% | |
| Form 8-K CASTLE BIOSCIENCES INC For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -4.24% | -1.00% | |
| Form S-8 CASTLE BIOSCIENCES INC | SEC filing · Form S-8 | SEC EDGAR | -4.24% | -1.00% | |
| Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis | Press release | GlobeNewswire | -1.99% | -7.59% | |
| Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 | Press release | GlobeNewswire | +1.03% | -7.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CSTL section they belong to.
Where else CSTL is measured.
CSTL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Castle Biosciences, Inc. - Common stock's median reaction calculated?
Every labeled CSTL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 524 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CSTL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CSTL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.